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ABSTRACT
Objectives: To capture an accurate contemporary
description of the practice of pulmonary
metastasectomy for colorectal carcinoma in one
national healthcare system.
Design: A national registry set up in Spain by Grupo
Español de Cirugía Metástasis Pulmonares de
Carcinoma Colo-Rectal (GECMP-CCR).
Setting: 32 Spanish thoracic units.
Participants: All patients with one or more
histologically proven lung metastasis removed by
surgery between March 2008 and February 2010.
Interventions: Pulmonary metastasectomy for one or
more pulmonary nodules proven to be metastatic
colorectal carcinoma.
Primary and secondary outcome measures: The
age and sex of the patients having this surgery were
recorded with the number of metastases removed,
the interval between the primary colorectal cancer
operation and the pulmonary metastasectomy, and
the carcinoembryonic antigen level. Also recorded were
the practices with respect to mediastinal
lymphadenopathy and coexisting liver metastases.
Results: Data were available on 543 patients from 32
units (6–43/unit). They were aged 32–88 (mean 65)
years, and 65% were men. In 55% of patients, there was
a solitary metastasis. The median interval between the
primary cancer resection and metastasectomy was
28 months and the serum carcinoembryonic antigen was
low/normal in the majority. Liver metastatic disease was
present in 29% of patients at some point prior to
pulmonary metastasectomy. Mediastinal
lymphadenectomy varied from 9% to 100% of patients.
Conclusions: The data represent a prospective
comprehensive national data collection on pulmonary
metastasectomy. The practice is more conservative than
the impression gained when members of the European
Society of Thoracic Surgeons were surveyed in 2006/
2007 but is more inclusive than would be recommended
on the basis of recent outcome analyses. Further
analyses on the morbidity associated with this surgery
and the correlation between imaging studies and
pathological findings are being published separately by
GECMP-CCR.
ARTICLE SUMMARY
Article focus
▪ Surgical excision of lung metastases from colo-
rectal cancer has been practiced with increasing
frequency for 50 years.
▪ Belief in effectiveness is based on clinical impres-
sion and retrospective analysis of over 90 selected
case series; there have been no controlled studies.
▪ A European Society of Thoracic Surgeons
working group found the evidence insufficient to
make recommendations.
▪ This study provides a hitherto missing element
which is a record at a population level of the
selective nature of this practice and the charac-
teristics of patients having this surgery.
Key messages
▪ A prospective registry captured data on patients
having pulmonary metastasectomy among an esti-
mated 60% of the Spanish population.
▪ Patients having this surgery are highly selected,
representing fewer than 1 in 20 patients with meta-
static colorectal cancer. Of them, 55% had a soli-
tary metastasis, and in 36% the interval between
primary surgery and metastasectomy was more
than 3 years, features which are likely to be asso-
ciated with a good natural history and are not the
typical pattern of advanced colorectal cancer.
▪ Many patients operated on had three or more
metastases resected (25%) and/or metastasect-
omy within 1 year (17%) and on existing evi-
dence, these can be expected to have early
recurrence and poor survival.
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INTRODUCTION
Colorectal carcinoma is the commonest cancer for
which pulmonary metastasectomy is undertaken.
Pulmonary metastasectomy for colorectal cancer is
widely practiced and is included in the UK’s National
Institute for Health and Clinical Excellence guidance.1 2
Belief in its effectiveness in improving survival relies on
more than 90 surgical follow-up studies3 going back to
the 1960s4 (ﬁgure 1). Several systematic reviews3–7 have
been published, the most recent in 2013 summing up
the available evidence as follows: “There were no pro-
spective randomized study, and most articles reported a
single-center experience of fewer than 80 patients oper-
ated during a time period of 15–20 years.”3 While surgi-
cal removal of lung metastases is widely accepted to be
beneﬁcial ‘in selected patients’, it was argued more than
30 years ago that the perception of beneﬁt may arise
from the selection of favourable cases for surgery rather
than a real beneﬁt attributable to surgery.8
The European Society of Thoracic Surgeons (ESTS),
aware that the practice of pulmonary metastasectomy was
increasing, initiated in 2006 the Lung Metastasectomy
Project. Its ﬁrst product was a survey of the opinions and
beliefs of its members. The data suggested widespread,
liberal and uncontrolled use of this surgery in European
practice.9 Most responding surgeons believed that there
was no deﬁned limit to the number of metastases that
should be removed, over 90% were prepared to operate
for metastases appearing within a year of primary resec-
tion, and three quarters were prepared to remove syn-
chronous pulmonary metastases. This was in contrast to
the then published evidence on practice. In the largest of
the systematic reviews, including data on 3504 patients,
60% of operations were for solitary metastases, the average
interval between primary surgery and metastasectomy was
36 months and 60% of patients were dead within 5 years.4
After a comprehensive review of the published evidence,
the leaders of the ESTS Project reported “that although
there was great experience in performing this surgery, the
belief in its beneﬁt relied on clinical case series and regis-
try reports. Evidence fell well short of Evidence Based
Medicine standards and robust guidance could not be pro-
duced on this basis.”10 It was clear to the ESTS project
leaders that better evidence was needed.10 As a result, a
randomised trial, PulMiCC (Pulmonary Metastasectomy in
Colorectal Cancer), is recruiting internationally in
Europe.11
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The strength of the study is that it captures prospectively the
number and nature of patients in a representative national
practice during a 2-year period.
▪ The data are limited to patients who had metastasectomy for a
proven colorectal metastasis.
▪ This is an observational study of practice; survival among
these patients will be presented in a future publication.
Figure 1 The start mid point and end dates of 51 reported series in the systematic review by Fiorentino et al.4 The vertical
coloured bands delineate quintiles in accrual of the 3504 patients in the quantitative synthesis.
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Not only is there a lack of evidence after 50 years of
increase in the number of patients having this surgery
but also there are no data concerning the features of
patients actually having this surgery in clinical practice.
The information cannot be derived from the grouped
data of retrospectively identiﬁed patients in follow-up
studies. Furthermore, there are inherent reporting and
publication biases making published data on outcomes
from specialist institutions an unreliable source of infor-
mation on practice nationally. The need for data on
current practice led to the formation of Grupo Español
de Cirugía Metástasis Pulmonares de Carcinoma
Colo-Rectal (GECMP-CCR; the Spanish Group) under
the auspices of Sociedad Española de Neumologa y
Cirurga Torácica (SEPAR) in order to obtain high
quality data nationwide in a short and deﬁned time
window to document existing practice in a healthcare
system.
METHODS
Study group
GECMP-CCR-SEPAR (the Spanish Group) was consti-
tuted in January 2008. The entry criterion for thoracic
surgery departments to be members of the group was to
have performed at least ﬁve procedures of lung metasta-
sectomy for colorectal carcinoma annually during the
period 2005–2007. Departments performing fewer
operations were not included but for those included in
the group on that criterion, data were accepted whether
or not that rate was maintained.
Database
The database created in discussion with the group is
composed of over 160 elements in ﬁve groups:
1. Primary colorectal cancer characteristics comprising
33 elements.
2. Time elapsed from primary resection to the ﬁrst lung
metastasectomy comprising 17 elements.
3. Lung metastasectomy episodes, up to a maximum of
ﬁve episodes with 80 elements each.
4. Relapse following each lung metastasectomy: 30 vari-
ables for each episode.
5. Study response variables including losses to follow-up
(details available as a web extra).
Publications commonly refer to the disease-free inter-
val or ‘DFI’. The patient is by deﬁnition not ‘disease
free’ and the data of ﬁrst evidence of recurrence are
unreliable. What is calculated in this paper (and is com-
monly given as DFI) is the interval between the primary
operation and the pulmonary metastasectomy, referred
to in this paper as the interoperative interval.
Patient inclusion criteria
Data were collected on patients who had a ﬁrst lung
metastasectomy operation between 1 March 2008 and 28
February 2010. Lung resection had to be performed
with radical intent (that means complete resection of
each metastasis) and there had to be no evident residual
malignant disease in the lung at the end of the surgical
procedure. There had to be histological conﬁrmation
that at least one of the lesions excised was consistent
with lung metastasis from colorectal carcinoma. The
presence of microscopic residual disease, as indicated by
positive margins, was not a reason for exclusion.
Microscopically detected cancer at the resection margin
was registered as R1 disease, regardless of whether it
involved parenchymal, vascular or bronchial margins.
In some patients, it was the resection of a lung metas-
tasis, as a diagnostic procedure, which led to the diagno-
sis and treatment of colorectal cancer with curative
intent. These patients are included in the database.
Patients were not included if the resection of the lung
nodule was a purely diagnostic procedure and no cura-
tive colorectal surgery was performed or if there was an
occult primary which remained so until the end of the
recruitment period.
Preoperative detection of lymph node involvement
No requirement was placed on the responding units to
conform to a protocol for lymph node staging, but
where done, positron emission tomography (PET) and
PET/CT ﬁndings were recorded.
Lymphadenectomy and lymph node involvement
A common nomenclature was used for intraoperative
lymphadenectomy techniques: (1) systematic lymph
node dissection (including lobe-speciﬁc lymph node
dissection) according to the deﬁnition of the
Bronchogenic Carcinoma Cooperative Spanish Group;
(2) systematic sampling: according to the deﬁnition of
the Bronchogenic Carcinoma Cooperative Spanish
Group and (3) minor lymphadenectomies: any other
selective lymphadenectomy.
To be considered Stage N0p, there had to be at least
systematic sampling or the disease was stage Nxp.
Data on associated liver metastases and their treatment
Associated liver metastases were recorded at three time
points: as being present at the time of the primary resec-
tion, appearing after the primary resection or being
present at the time of the pulmonary metastasectomy. In
each case, the number treated was recorded.
Analysis
Descriptive analyses of patient demography, primary
colorectal cancer and the metastatic disease for the total
patient population were carried out. The analysts (FF
and TT) relied on the centres’ internal quality control
for the veracity of all entries related to imaging and
pathological diagnosis. Missing, outlying or implausible
data were queried through direct enquiry with the data
collectors at the various centres (RE). If items were
missing, we retained the data available and stated the
diminished denominator for that analysis. Simple
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descriptive statistical analysis was carried out looking at
the mean, median, CIs and centiles according to the
nature of the data and their distribution. The data
report practice: there was no plan to draw any statistical
inferences. The only subgroup analysis performed in
this phase was by centre and this is for descriptive pur-
poses only.
RESULTS
Centres and patients
Of the 35 centres that enrolled to submit data, 32 pro-
vided data for inclusion in the Spanish registry. There
are 543 records in the database. The accrual of patients
per centre is shown in ﬁgure 2. There were 6–43 patients
per centre (median 16; IQR 10–23; N=543). There were
65% men and 35% women (N=541; ﬁgure 3). The
mean age at the time of pulmonary metastasectomy was
65 years (range 32–88 years, SD 10.2, N=529). The age
distributions, centre by centre, are displayed in ﬁgure 4.
Site of primary colorectal cancer
The site of the primary is shown in ﬁgure 5 for 526
tumours where a single location was recorded. In seven
cases, non-adjacent colorectal sites were recorded, sug-
gesting multiple primaries.
Number of metastases removed
Pulmonary metastases removed (1, 2, 3 and 4+) are
shown centre by centre in ﬁgure 6. For 532 patients for
whom the data are available, 293 (55%) had a solitary
metastasectomy; 104 (19.5%) had two, 67 (12.6%) had
three and 68 (12.9%) had four or more metastases
resected. The frequency distribution of the number of
metastases per operation shows the preponderance of
solitary and low number metastases (ﬁgure 7).
Interoperative interval
The interval between resection of the primary and the
metastasectomy is shown in ﬁgure 8. Based on data from
524 patients, the median interval was 28 months (IQR
16–43 months). In 17% (87 patients) the interval was
under 12 months, in 47% (247) it was 12–36 months
and in 36% (190 patients) it was over 36 months
(N=524).
Carcinoembryonic antigen status
Carcinoembryonic antigen (CEA) at the times of assess-
ment for metastasectomy was recorded in 414 patients.
Among these, the median CEA was 2.72 (IQR 1.42–7).
The distributions of the measurements by centre are
shown in ﬁgure 9. Of the 414 patients, 125 (30%) had
CEA assays above 5 ng/ml and 67/414 (16%) had CEA
greater than 10 ng/ml.
Lung metastasectomy after previous liver metastasectomy
In summary, 155 patients (29%) had one or more liver
metastases at some time prior to pulmonary metasta-
sectomy. For 32 units, the liver metastasis rate ranged
Figure 2 Accrual patterns for patients in the study. A few centres entered the study after 1 March 2008 to the end of February
2010. Data accrual for the late joiners appears to be consistent within the time frame of submission and there is no reason to
think it was not a representative picture in practice.
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from 0% to 56% (median 25%; IQR 19–33%). In more
detail, with respect to the time of liver metastases, of
the 543 patients, 79 (14.5%) had liver metastases at the
time of primary colorectal resection, 104 (19.2%) had
metastases which appeared during the interoperative
interval and 45(8.3%) at the time of pulmonary metas-
tasectomy. Figure 10 shows the variation by unit in the
presence of metastases at each of these times. The pro-
portions treated at each of those times were 14%, 19%
and 7.7%, respectively. These counts are not mutually
exclusive and an individual patient could feature in
one, two or all three counts because the appearance,
evaluation and treatment of metastases is a dynamic
process.
Figure 3 The number of cases per unit shown as men (blue) and women (red).
Figure 4 The age distribution for each centre showing the median, IQR, 10th and 90th centiles and extreme values.
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Completeness of resection
In 95% of patients, there was R0 resection (no cancer at
the resection margin at microscopy). The R1 resection
rates by unit ranged from 0% to 22% (median 0; IQR
0–7%). It should be noted that these rates are unstable.
The actual numbers for the unit with the highest rate
were two R1 resections among nine patients for a rate of
22% (95% Conﬁdence Limits 3–60%). More or fewer
R1 resections would radically alter ranking when there
are numbers both of events and denominators.
Mediastinal staging prior to pulmonary metastasectomy
PET data for mediastinal nodes were recorded in 388/
543 (71.4%) patients. Of these 388, the stages were N0
in 357 (92%), N1 in 7 (1.8%), N2 in 15 (3.9%) and N3
in 9 (2.3%).
Lymphadenectomy
The overall proportion of patients among the 543 who
underwent lymphadenectomy according to the deﬁni-
tions included systematic lymph node dissection (9%),
systematic sampling (18%) and minor lymphadenectomy
(19%). The patients having any form of lymphadenect-
omy varied by centre from 9% to 100% (median 40%;
IQR 29–60%). These are mutually exclusive and are
shown in ﬁgure 11 with the contribution of the three
types indicated within the total proportion having any
form of lymphadenectomy.
DISCUSSION
The Spanish Group’s registry represents the largest data
set of prospectively collected cases of pulmonary metas-
tasectomy for colorectal cancer known to us.
Contemporary patient-level data are not available from
any other published source. The International Registry
of Lung Metastasectomy published 15 years ago did not
separately identify colorectal cancer metastases.12
Systematic reviews, such as those from Pfannschmidt
et al56 and Gonzalez et al3 and the most inclusive, a quan-
titative synthesis of 51 papers summarising data on 3504
patients,4 are properly regarded as secondary sources
because they rely on amalgamation of already grouped
data. The largest primary data source of which we are
aware is the combined series from Duke and the
Memorial Sloan-Kettering Cancer Centre comprising
378 patients over a 10-year period from 1998 to 2007
and published in 2009.13
By contrast with these retrospectively collected data
sets, the Spanish registry patients were identiﬁed pro-
spectively and collected from as many centres as possible
within a short time frame of 2 years. The 32 Spanish hos-
pitals contributing to the study take care of 28 million
people, around 60% of the Spanish population (46.6
million in 2009). Based on the work of the ESTS Lung
Metastasectomy Project10 and the many reports of indi-
vidual series from many European countries, these data
are believed to be representative of current European
practice.
Case selection in the Spanish registry and published
cohorts versus surgeon reported beliefs
The most striking ﬁnding is the contrast between this
2-year snapshot of practice and what thoracic surgeons
responding to the ESTS survey thought to be their
practice.9 The reality is much more selective and conser-
vative than believed by surgeons responding to the ESTS
survey, with respect to the number of metastases
removed and the interval since resection of the primary.
Figure 5 Location of the primary colon and rectal tumours.
About 46% of the metastatic were from the rectum while
usually about a third of the primary colorectal cancers are in
the rectum. This excess is maybe because the systemic
venous drainage of the rectum is more likely to allow lung only
or lung first metastases while colon cancer may metastasise
selectively to the liver via the hepatic portal vein. This
simplistic anatomical explanation is disputed, but there are
data to support the differential lung/liver metastasis
predilection.24
Figure 6 The centre-by-centre number of metastases
resected in individual cases.
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Quantitative synthesis of the historical data in the system-
atic reviews shows the practice, as reported in surgical
follow-up studies, to be dominated by patients with fewer
metastases, and a longer interoperative interval and
non-elevated CEA.4 5 These factors are known from
repeated multivariate analyses to be associated with
better 5-year survival rates after metastasectomy.3 7 It
should not be overlooked that these factors are also
those associated with a more favourable natural history.
Some characteristics of the patients in the Spanish
group’s registry are shown in table 1, in comparison to
the largest known aggregation of data that we are aware
Figure 7 Frequency distribution of the metastatic number.
Figure 8 The interval between primary resection and pulmonary metastasectomy: median, IQR, 10th and 90th centiles and
outliers.
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of, from the systematic review and quantitative synthesis4
and the large Duke/MSK-CC.13 The time frame of the
former is wide, going back to the 1960s, while the latter
is more constrained (1998–2007), but the data are
broadly similar. The 5-year increase in average age of the
patients is as might be expected when recent practice is
compared with that of even a few years ago. The Spanish
data are comparable with observational data from other
sources, and therefore it is the survey which is mislead-
ing.9 Surgeons’ recollections of what they do are not
necessarily in line with the documented record of
practice.
Number of metastases and the interval between primary
surgery and metastasectomy
The two most consistently reported factors related to sur-
vival are the number of metastases and the interval
between resection of the primary cancer and metasta-
sectomy. There has been a tendency to allow optimism
to expand the criteria for metastasectomy. Although
there have been many publications exploring favourable
and unfavourable factors for survival, authors have only
recently explicitly stated groups of patients who gain no
survival beneﬁt. Onaitis et al13 (Duke and MSK-CC) were
unusual in this regard and stated, “Medical management
alone should be considered standard for patients who
have both three or more pulmonary metastases and less
than 1 year DFI.” The Spanish registry data for number
and interval are plotted in ﬁgure 12 demarcating
patients above and to the right of these red lines. The
latest meta-analysis derived an HR for poor outcome
which doubles for multiple metastases (HR 2.04, 95% CI
1.72 to 2.41) and multiple means simply more than
one,3 concurring with the ﬁndings of an earlier study in
which the more favourable outcomes were in patients
with no more than one metastatic lesion7 (marked in
amber in ﬁgure 12). Nevertheless, the authors conclude,
‘it seems currently unfair to deny surgery for those
patients with two to four lesions’.3 This value laden state-
ment depends on what is meant by ‘unfair’. Some might
think it unfair to be put through surgery when beneﬁt is
improbable.
There are obvious technical considerations in prefer-
ring to offer an intervention to patients with fewer
metastases. A proposal has been made to regard the
existence of a few metastases as an entity, the oligometa-
static state14 15 set at ﬁve or fewer by its protagonists.
The sobriquet has been applied to colorectal cancer,7
but it may be more plausible to regard the fewness of
metastases as nothing other than the tail of a skewed dis-
tribution in which the fewer metastases are simply a
marker for less aggressive cancer. However, the fewer
metastases there are, the more interesting they are to
practitioners. Oligometastasis represent a therapeutic
opportunity not only for surgery but also for radiofre-
quency ablation and the latest radiotherapy techniques
(SBRT)16 with which there is an upper limit in terms of
practicalities to how many metastases can be removed.
In contrast, but unrepresentative of practice, according
to a report advocating laser as a tool to allow the lung
parenchyma to be spared in open surgery, as many as
124 metastases were resected.17 In general, the fewer the
Figure 9 Carcinoembryonic antigen by centre: median, IQR, 10th and 90th centiles and outliers.
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number of metastases, the more likely is metastasectomy
to be offered.
For the interoperative interval, the clinical incentives
work in the opposite direction. The effect can be seen
in ﬁgure 12 where surgeons select patients with fewer
metastases but evidently are not able to restrict surgery
to those with longer intervals. There can be no absolute
threshold proposed along the time continuum but indi-
cative intervals, below which long survival cannot be
anticipated, are variably suggested at 12 months,13 in the
range of 19–39 months3 and 36 months7 in recent
pooled analyses. Interpretation is made more difﬁcult
Figure 10 Proportion of patients in each centre who had liver metastases at the time of the primary resection (blue), appeared
since the primary resection (maroon) or were present at the time of the pulmonary metastasectomy. For ease of reading, they
are ranked by those appearing subsequent to primary resection, but the data are not aggregated because the counts are not
mutually exclusive and there is a dynamic process of metastases appearing and being treated.
Figure 11 Proportion of patients having any lymphadenectomy in each centre, ranked by overall number with systematic lymph
node dissection in blue, systematic sampling in maroon and minor lymphadenectomies in yellow.
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because not all studies use the same deﬁnition of DFI.
Some authors use the interoperative interval as a surro-
gate for the DFI (as we have carried out here), but
others used the exact interval from primary colorectal
surgery to the time when the metastatic lesions were ﬁrst
detected following that primary surgery.7 Gonzalez et al3
remarked on the problem of meta-analysis when authors
provided the information in different ways. Common
reporting standards would certainly make analytical
work easier.18 But however it is deﬁned, if the metastases
are detected early, a deliberate policy of waiting to
ensure that these are not the few of many more to come
must be unbearable for many patients, set against a
hope for cure and the sense of a missed opportunity.
The perception that there is any advantage in haste is
not based on the evidence that already exists in observa-
tional studies.
Carcinoembryonic antigen
Of the patients in the Spanish registry in whom CEA was
measured, it was elevated (CEA>5 ng/ml) in 30%.
During the 1980s, a CEA assay was proposed to trigger
asecond-look laparotomy including inspecting the liver
with a view to resection. A randomised trial found that
this increased the number of operations but not the sur-
vival of the patients.19 20 Some oncologists continue to
use a CEA assay as a means of surveillance to trigger
further imaging and if lung metastases are discovered,
this may lead to a referral to a thoracic surgeon for their
removal.21 A thoracic surgeon, aware of the evidence,
would rightly be inclined to advise against surgery
because elevated CEA is a marker for a poor
outcome.3 4 6 This sends mixed messages and the risk of
confusion in the minds of patients.22
Figure 12 Scatterplot of the interoperative interval and number of metastases. The red lines demarcate the thresholds (an
interval of less than 12 months and 3 or more metastases) beyond which outcomes were always poor in the Duke/MSK-CC
experience.13 The amber lines demarcate the thresholds in most of the meta-analyses by Gonzales et al,3 again indicating the
patients likely to recur above and to the right of the pair of lines. The factors which are favourable for survival (solitary metastasis
and long interval) are to the bottom left of the graph where one might anticipate the concentration of patients to be. It appears
that selecting patients with fewer metastases occurs more naturally than deliberately delaying surgery for the selected few with
longer intervals.
Table 1 Basic elements of the data included in the
Spanish Registry (GECMP-CCR-SEPAR) are compared
with those in the most comprehensive systematic review4
of 51 retrospective studies and the combined Duke and
MSK-CC follow up study13
GECMP
N=543*
Systematic
review4
N=2504
Onaitis13
N=378
Mean age (years) 65 60 61
Sex (%male) 65 60 60
Solitary metastases 55 60 60
Median interval
since primary
resection (months)
28 36 24
Given the very large time scale of about 50 years of practice
represented altogether, the case selection is remarkably similar.
*Some data are missing from the Spanish registry. The
denominators are 529 for age, 541 for sex, 532 for the count of
metastases and 524 for the interoperative interval. The
percentage is of those where data are available.
GECMP, Grupo Español de Cirugía Metástasis Pulmonares.
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Lung and liver metastasectomy
The practice of hepatic resection of colorectal liver
metastases, in selected patients, was adopted internation-
ally by the late 1990s.23 The liver is the commonest site
of metastases and the route of spread is via the liver,
which explains the excess of lung ﬁrst or only metastases
with rectal cancer compared with colon cancer.21 24 An
innovative analysis from the Cleveland Clinic of patients
who have had hepatic resection for metastases, and sub-
sequently were found to have lung metastases, was used
to argue in favour of resection of both, but in very
highly selected patients.25 However, the shape of the sur-
vival curve is unlike that of usual cancer survival because
the performance of the second operation (in whichever
order) is conditional on having survived and recovered
from the ﬁrst to be considered for the second. Recent
European studies report that patients who have had
hepatic resection are increasingly being referred for pul-
monary metastasectomy. The series are small with
17/8426 and 27/7027 of the patients having pulmonary
metastases having had prior liver resection (about 20%
and 40%). Of the patients in the Spanish registry, based
on much larger numbers, 29% (155/543) had prior
liver metastasectomy. The wide variation among centres
(0–56%) is likely to reﬂect referral patterns. Thoracic
surgeons working in a hospital with liver surgery are
more likely to be referred patients from other centres
not performing liver resections. With respect to survival
for those with liver and lung resection, of note are the
ﬁnal words of the larger of these series: “prolonged
disease-free survival remains the exception, and seems to
occur only in patients with a single lung lesion.”27
Degree of selection and its effect
The starting point for cases in the Spanish registry is
that they had a proven metastasis resected. The popula-
tion denominator from which these patients were drawn
is not known, and nor is the number of patients consid-
ered for metastasectomy, or the number of patients who
had a nodule removed which proved not to be a metas-
tasis. This is a limitation in common with most clinical
reports, nearly all of which are follow-up studies.
Spanish cancer registry data allow an estimate of the
proportion of patients with colorectal cancer who
feature in the Spanish metastasectomy registry. The inci-
dence of colorectal cancer in the Spanish population is
of the order of 45 men and 35 women/100 000.28 Based
on an estimated population base of 28 million, the
number of patients with colorectal cancer in a 2-year
period would have been around 22 400 cases of whom
about half might have had metastatic disease. Based on
these estimates, the patients in the dataset might repre-
sent about 5% of patients with metastatic colorectal
cancer or 2.5% of all patients with colorectal cancer.
A report from Turin from three hospital databases
identiﬁed 1411 patients with metastatic colorectal cancer
recorded between 1994 and 2010.29 Of them, 50 patients
(3.5%) were selected to have pulmonary metastasectomy.
In a Japanese study of patients who had an R0 curative
resection of colorectal cancer from 2000 to 2006, 18/764
(2.4%) were selected for pulmonary metastasectomy.21
We can say no more than that the selected proportion of
patients in the Spanish registry is of a similar order of
magnitude to that in other reports where some estimate
of the denominator is available. What is consistent is that
only 1 in 30–40 patients with advanced colorectal cancer
have pulmonary metastasectomy. There remains the pos-
sibility that the subsequent survival of these patients owes
more to selection of a subset of inherently more favour-
able cases than being attributable to the effect of the pul-
monary metastasectomy.8 30
Solitary nodules of unknown histology
Patients who had an excision of a solitary nodule, which
proved not to be a colorectal cancer metastasis, are not
recorded in the Spanish registry. The colorectal surveil-
lance pathway overlaps with the clinical pathway for
patients who present with a solitary pulmonary nodule.31
The research question in the present study is thus nar-
rowed to only patients in whom the nodule proved to be
a colorectal cancer metastasis. There have to be bound-
aries to a data retrieval exercise, but this post hoc entry
criterion should be remembered if these data are used
outside their intended purpose.
Case for a randomised control trial
The leaders of the ESTS Working Group concluded, “In
the absence of a randomized controlled trial looking at
the effectiveness of pulmonary metastasectomy on sur-
vival and quality of life, it is unlikely that the current
practice will ever be inﬂuenced.” The randomised trial
that emanated from the working group’s deliberations
(PulMiCC)32 33 is open internationally. The Spanish
population-based study cannot answer questions about
effectiveness in any patient group but does provide
information about practice against which the generalis-
ability of a randomised trial can be tested.
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